Successful treatment with tocilizumab in a case of Cogan's syndrome complicated with aortitis

Modern Rheumatology

Volumn 23, Issue 3, 2013, Pages 577-581

  Shibuya, Mihoko ^a   Fujio, Keishi ^a   Morita, Kaoru ^a   Harada, Hiroaki ^a   Kanda, Hiroko ^a   Yamamoto, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Aortitis; Cogan's syndrome; IL 6; Tocilizumab

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; PREDNISOLONE; SERUM ALBUMIN; TOCILIZUMAB;

AGED; AORTITIS; ARTHRITIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COGAN SYNDROME; ERYTHROCYTE SEDIMENTATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPLANTATION; IRITIS; MALE; MENINGITIS; PANNICULITIS; PERCEPTION DEAFNESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RELAPSE; REMISSION; TREATMENT DURATION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; AORTITIS; COGAN SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; TREATMENT OUTCOME;

EID: 84877730651     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0691-0     Document Type: Article

References (36)

1. Haynes BF, Kaiser-Kupfer MI, Mason P, Fauci AS. Cogan syndrome: studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine (Baltimore). 1980;59:426-41.
2. Gluth MB, Baratz KH, Matteson EL, Driscoll CL. Cogan syndrome: a retrospective review of 60 patients throughout a half century. Mayo Clin Proc. 2006;81:483-8.
3. Grasland A, Pouchot J, Hachulla E, Bletry O, Papo T, Vinceneux P. Typical and atypical Cogan's syndrome: 32 cases and review of the literature. Rheumatology (Oxford). 2004;43:1007-15.
4. Weyn T, Haine S, Conraads V. Cogan's syndrome with left main coronary artery occlusion. Cardiol J. 2009;16:573-6.
5. Udayaraj UP, Hand MF, Shilliday IR, Smith WG. Renal involvement in Cogan's syndrome. Nephrol Dial Transplant. 2004;19:2420-1.
6. Raza K, Karokis D, Kitas GD. Cogan's syndrome with Takayasu's arteritis. Br J Rheumatol. 1998;37:369-72.
7. Emilie D, Liozon E, Crevon MC, Lavignac C, Portier A, Liozon F, et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol. 1994;39:17-24.
8. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36:1286-94.
9. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford). 2006;45:545-8.
10. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-7.
11. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008;58:1197-200.
12. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012;51:151-6.
13. Cogan DG, Grant WM. Keratitis due to N-butyl alcohol. Arch Ophthalmol. 1945;34:248.
14. Kondo Y, Ito S, Ohi Y, Satou H, Hiraoka T, Tsuboi H, et al. Atypical Cogan's syndrome with aortitis. Intern Med. 2009;48:1093-7.
15. Haynes BF, Pikus A, Kaiser-Kupfer M, Fauci AS. Successful treatment of sudden hearing loss in Cogan's syndrome with corticosteroids. Arthritis Rheum. 1981;24:501-3.
16. Ghadban R, Couret M, Zenone T. Efficacy of infliximab in Cogan's syndrome. J Rheumatol. 2008;35:2456-8.
17. Fricker M, Baumann A, Wermelinger F, Villiger PM, Helbling A. A novel therapeutic option in Cogan diseases? TNF-alpha blockers. Rheumatol Int. 2007;27:493-5.
18. Beccastrini E, Emmi G, Squatrito D, Vannucchi P, Emmi L. Infliximab and Cogan's syndrome. Clin Otolaryngol. 2010;35:441-2.
19. Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 2002;132:414-22.
20. Orsoni JG, Lagana B, Rubino P, Zavota L, Bacciu S, Mora P. Rituximab ameliorated severe hearing loss in Cogan's syndrome: a case report. Orphanet J Rare Dis. 2010;5:18.
21. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011;13[Suppl 1]:S5.
22. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5:1731-40.
23. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88-96.
24. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987-97.
25. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516-23.
26. Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol. 2011;21:10-5.
27. Seko Y, Sato O, Takagi A, Tada Y, Matsuo H, Yagita H, et al. Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis. Circulation. 1996;93:1788-90.
28. Beyer C, Axmann R, Sahinbegovic E, Distler JH, Manger B, Schett G, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis. 2011;70:1874-5.
29. Lee KH, Cho A, Choi YJ, Lee SW, Ha YJ, Jung SJ, et al. The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with Takayasu arteritis. Arthritis Rheum. 2012;64:866-75.
30. Scheel AK, Meller J, Vosshenrich R, Kohlhoff E, Siefker U, Muller GA, et al. Diagnosis and follow up of aortitis in the elderly. Ann Rheum Dis. 2004;63:1507-10.
31. Arnaud L, Haroche J, Malek Z, Archambaud F, Gambotti L, Grimon G, et al. Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum. 2009;60:1193-200.
32. Blockmans D. PET in vasculitis. Ann N Y Acad Sci. 2011;1228:64-70.
33. Koutantji M, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum. 2003;49:826-37.
34. Carpenter DM, Thorpe CT, Lewis M, Devellis RF, Hogan SL. Health-related quality of life for patients with vasculitis and their spouses. Arthritis Rheum. 2009;61:259-65.
35. Tomasson G, Boers M, Walsh M, LaValley M, Cuthbertson D, Carette S, et al. Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken). 2012;64:273-9.
36. Basu N, Jones GT, Fluck N, MacDonald AG, Pang D, Dospinescu P, et al. Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatology (Oxford). 2010;49:1383-90.